G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $261,000 | -25.4% | 34,400 | +0.3% | 0.00% | – |
| Q4 2021 | $350,000 | -23.9% | 34,300 | 0.0% | 0.00% | – |
| Q3 2021 | $460,000 | -38.9% | 34,300 | 0.0% | 0.00% | – |
| Q2 2021 | $753,000 | -19.7% | 34,300 | -12.1% | 0.00% | – |
| Q1 2021 | $938,000 | +119.2% | 39,000 | +63.9% | 0.00% | – |
| Q4 2020 | $428,000 | -15.9% | 23,800 | -46.0% | 0.00% | – |
| Q3 2020 | $509,000 | -53.3% | 44,100 | -1.8% | 0.00% | -100.0% |
| Q2 2020 | $1,089,000 | +120.0% | 44,900 | 0.0% | 0.00% | – |
| Q1 2020 | $495,000 | -58.3% | 44,900 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $1,187,000 | +9.7% | 44,900 | -5.5% | 0.00% | 0.0% |
| Q3 2019 | $1,082,000 | -25.7% | 47,500 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,456,000 | +229.4% | 47,500 | +78.6% | 0.00% | – |
| Q1 2019 | $442,000 | -20.9% | 26,600 | -8.9% | 0.00% | – |
| Q4 2018 | $559,000 | -64.2% | 29,200 | -2.3% | 0.00% | -100.0% |
| Q3 2018 | $1,563,000 | +20.3% | 29,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,299,000 | – | 29,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |